Pulmatrix Stock News

Landos Biopharma (NASDAQ:LABP) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation. Profitability This table compares Landos Biopharma and Pulmatrixs net margins, return on equity and return on []

Surgalign Holdings, Inc. (SRGA) with the stream of -4.31% also noticed, India Pulmatrix, Inc. (PULM) encountered a rapid change of -3.85% in the last hour of trading session. Surgalign Holdings, The post Have a sight on this: Surgalign Holdings, Inc. (NASDAQ:SRGA), Pulmatrix, Inc. (NASDAQ:PULM) appeared first on Stocks Equity .

Trevena, Inc. (TRVN) with the stream of -1.79% also noticed, India Pulmatrix, Inc. (PULM) encountered a rapid change of -2.84% in the last hour of Monday’s trading session. Trevena, Inc. … The post A Few Positives and Negatives For: Trevena, Inc. (NASDAQ:TRVN), Pulmatrix, Inc. (NASDAQ:PULM) appeared first on Stocks Equity .

Wunong Net Technology Company Limited (WNW) with the stream of -7.46% also noticed, India Pulmatrix, Inc. (PULM) encountered a rapid change of -0.38% in the last hour of Tuesdays trading The post Is It Overvalued? Look at the P/S Ratio: Wunong Net Technology Company Limited (NASDAQ:WNW), Pulmatrix, Inc. (NASDAQ:PULM) appeared first on Stocks Equity .

Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of -28.57% and -56.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

LEXINGTON, Mass., Aug. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non

The stock price of Pulmatrix Inc (NASDAQ: PULM) increased by over 4% pre-market. This is why it happened.

LEXINGTON, Mass., May 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-

LEXINGTON, Mass., April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and no

LEXINGTON, Mass., April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading "Updated PUR1800

LEXINGTON, Mass., March 23, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non

LEXINGTON, Mass., Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-